Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,663 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Recruiting Phase 1 Interventional

DK222 Study at Hopkins

NCT07140315
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
[18F]DK222 radiotracer
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea

NCT02387476
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep Apnea, OSA
Interventions
FRESCA mask first night, CPAP Mask first night
Device
Lead sponsor
FRESCA Medical
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Fresno, California • Murrieta, California • Hollywood, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 23, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

NCT00045617
View directory record Official record
Conditions
Lung Cancer
Interventions
monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody GD2 anti-idiotype vaccine, cisplatin, etoposide, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
99
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

NCT00001990
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab in combination with Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers

NCT01729689
View directory record Official record
Conditions
Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
counseling intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 23, 2026, 6:11 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Terminated Phase 1 Interventional Results available

Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)

NCT05027815
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Interventions
Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 23, 2026, 6:11 PM EDT
Completed No phase listed Observational

DIBH Proton Planning

NCT01386697
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Gastrointestinal, Lymphomatous Malignancies
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

NCT05017025
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Aurora A Kinase Inhibitor LY3295668, Osimertinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

NCT00095225
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
Interventions
Avastin (bevacizumab), Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Bakersfield, California • Concord, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 23, 2026, 6:11 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
34
States / cities
Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 23, 2026, 6:11 PM EDT
Not listed Not applicable Interventional

A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer

NCT01500876
View directory record Official record
Conditions
Lung Cancer
Interventions
4D-CT pre-treatment scan
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660517
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
MP29-02, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 23, 2026, 6:11 PM EDT
Completed No phase listed Observational

Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension

NCT00845013
View directory record Official record
Conditions
HIV Infection, Pulmonary Hypertension, Endothelial Function, HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

NCT00500578
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 23, 2026, 6:11 PM EDT
Active, not recruiting Phase 4 Interventional

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689
View directory record Official record
Conditions
Asthma
Interventions
Albuterol and budesonide inhalation aerosol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Recruiting Not applicable Interventional

Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy

NCT06987890
View directory record Official record
Conditions
Lung Cancer (NSCLC), Geriatric Assessment, Stereotactic Body Radiation Therapy (SBRT)
Interventions
Practical Geriatric Assessment
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720
View directory record Official record
Conditions
Covid-19
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions
Surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

NCT04414124
View directory record Official record
Conditions
Mild-to-moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

NCT01750281
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
13
States / cities
Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 23, 2026, 6:11 PM EDT